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Introduction
Nuclear medicine has been engaged in considerable transformational change; 
this is particularly true in the current decade. In part, this is due to developing 
technology, software algorithms, disease management pathways and models, 
and evidence based medicine. The merging of functional and anatomical 
technologies (‘hybrid imaging’, for example, SPECT-CT) is beginning to provide a 
more focused approach to disease management.
Within current clinical practice, various types of computed tomography (CT) 
confi gurations are available for purchase with a SPECT system, and the workload 
of a department as well as its fi nancial constraints will have an infl uencing factor 
on the fi nal specifi cations of such a purchase1. Historically, low resolution/dose, 
single slice CT units (eg GE Hawkeye) provided an initial platform to undertake 
routine clinical hybrid SPECT-CT imaging; more recently the advent of multi slice 
high resolution (diagnostic quality) CT has resulted in nuclear medicine centres 
utilising this technology in routine SPECT-CT clinical practice.
This article focuses on several aspects of SPECT-CT that appear to have particular 
importance within clinical practice. First, through case illustrations, an indication 
of where SPECT-CT has value is given; a debate is then raised about the added 
radiation dose that is incurred through CT. Building on this, the scope of practice 
of radiographers is considered in light of practitioner and referrer status2 for 
the CT component of SPECT-CT and, fi nally, education and training and business 
planning matters are considered.
Areas in which SPECT-CT has value
Attenuation Correction
An obese 43 year-old female who had experienced left sided chest pain 
underwent an exercise tolerance test (with ECG); no ST depression was noted. 
The origin of her cardiac related pain was required and, consequently, the patient 
underwent stress and rest myocardial perfusion imaging (MPI; see fi gure 1). The 
images shown are rest only; row A is not attenuation corrected (AC); row B is 
with CT AC applied. On comparing rows A and B, the attenuation induced photon 
defi cient artefact (on the non AC images) is corrected on the CT AC images, so 
ruling out potential myocardium infarction (the stress study demonstrated similar 
photon defi cient areas on the non AC images). This is an interesting case as the 
resting CT AC images rule out any problem in the inferior wall but pinpoint the 
problem in the anterior wall. This case illustrates that the use of attenuation 
correction in MPI should only be used as a tool to support decision making in 
relation to establishing the presence of attenuation artefacts3.
For certain SPECT studies non-homogeneous photon attenuation within the chest 
and abdomen has made diagnosis diffi cult. Non-homogenous attenuation can 
affect sensitivity and specifi city. To counteract this, AC can be used to counteract 
attenuation artefacts. Attenuation is an exponential process (linear attenuation 
coeffi cient); when measured, the value depends upon the proportion of scatter 
included in the measurement4. In SPECT imaging, the spatial distribution of the 
linear attenuation coeffi cient data and impact upon the raw projection data is 
unknown, and additional information (such as the information provided from CT) is 
required to correct for the effects of attenuation and/or scatter3.
Evidence suggests a necessity to interpret attenuation corrected studies as part 
of an overall quality control process3. This may include various steps but the 
added value of attenuation corrected images should be considered as part of the 
complete imaging process, and to aid the overall clinical decision making process. 
In terms of clinical studies which have utilised AC for cardiac imaging, the majority 
include small to medium sample sizes. Although Ficaro et al’s study in 19955 
included a limited number of patients (n=10), lateral-to-posterior and basal-to-
apical wall ratios of near unity value were demonstrated using AC. The use of AC is 
further supported in more recent research, also undertaken by Ficaro et al in 20026. 
Figure 1. Myocardial 
perfusion scan, rest 
images only. Row A = 
no AC; row B = CT AC 
applied.
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Additional studies by Prvulovich et al in 1997 and Hendel et al in 1999 
demonstrated improvements in diagnostic specifi city in patients with follow-up 
angiography, in comparison with non-attenuation corrected images7,8. It should, 
however, be noted that these studies were all conducted using radioisotope and 
transmission based attenuation correction units, not CT. In terms of the impact of 
attenuation correction on diagnostic sensitivity of MPI, Duvernoy et al’s study on 28 
patients with left main coronary artery disease in 20009 showed this to be present 
on 64 per cent of AC images versus seven per cent of uncorrected images. 
In the 1980s, the use of external transmission sources such as Ba-133 and Gd-153 
were utilised to provide attenuation correction data. However, issues related to 
poor statistical quality has resulted in a limited use of such sources within modern 
clinical practice. Nevertheless, in clinical instances whereby only AC is being 
performed, as in nuclear cardiology for example, the use of a transmission-based 
system may be justifi ed. Acquiring the required AC data using a transmission based 
system such as Gd-153 takes longer than a CT based method due to the large 
difference in available photon fl ux and the fact that transmission based systems 
have a limited fi eld of view coverage3. 
CT data may be used to create linear attenuation coeffi cients based upon 
anatomical detail specifi c to each patient. This data (attenuation map) may be 
used to correct for the effects of photon attenuation within the subject and, if only 
AC is being undertaken (eg myocardial perfusion imaging), the CT may be acquired 
with a lower statistical quality. Although this reduces the spatial resolution, this 
technique reduces the radiation dose to the patient.
With reference to oncology-based applications, CT AC has particular values. 
SPECT imaging is increasingly used to quantify the uptake of a particular 
radiopharmaceutical within tumours/organs. Such targets are quantifi ed in SPECT 
as volumes of interest (VOI); these are defi ned around the region to integrate the 
number of counts, which is directly proportional to the activity (expressed as MBq 
or mCi) in the volume defi ned10.
Accurate quantitative measurement of radioactivity from a SPECT study can be 
compromised by the effects of attenuation (and scatter). Such factors may be corrected 
by the use of CT AC data. The use of SPECT-CT is beginning to create a new role 
for nuclear medicine in terms of accurately quantifying radionuclide uptake within 
targets, compared to measurements undertaken with SPECT alone. Results from 
clinical studies11,12 have demonstrated the value of SPECT-CT in terms of measuring 
response to radiotherapy treatment for patients with non-Hodgkin’s lymphoma and 
radioimmunotherapy. The use of SPECT-CT within oncology is beginning to replicate 
clinical experience with PET-CT, in terms of improving localisation and extent of disease, 
and differentiation of physiological and pathological uptake.
Localisation
CT (low resolution or diagnostic quality) can be used in conjunction with SPECT 
to help localise cold or hot areas seen on SPECT imaging. This has particular 
value in cases where there are limited or no anatomical landmarks present on 
SPECT imaging and/or when such landmarks are present but greater anatomical 
spatial resolution is required. Examples with the registration of SPECT with CT for 
localisation purposes could include: to aid defi nitive diagnosis and to give more 
precise lesion localisation as part of surgical work up, such as sentinel lymph 
nodes13, radiotherapy treatment planning14 or initial patient treatment work up15 
(eg neuroendocrine tumours (NET)).
Advancements in computing power and software algorithms have also impacted 
upon the ability to compensate for the errors in SPECT imaging. In particular the 
inclusion of an iterative reconstruction model (eg OSEM) for the correction of 
attenuation with SPECT data and providing quantitative information is becoming 
more common within clinical practice10. Numerous studies have identifi ed the 
improved diagnostic accuracy of SPECT/CT over conventional SPECT imaging and 
the empirical evidence points toward the following areas of clinical practice which 
have benefi ted from the emerging hybrid imaging technology, for example:
 Lymphoma16 
 Lung Cancer16 
 Primary and secondary malignant bone disease17 
 Infection and infl ammation18 
 Abdominal disease19 
 Endocrinology15,20 
A comprehensive list of potential clinical applications for SPECT-CT has previously 
been published10 and the majority of applications relate to the anatomical 
localisation of tumours using various radiopharmaceuticals. Published research by 
Koral et al identifi ed the added value of SPECT-CT in terms of providing valuable 
tumour organ uptake and dosimetry data, enabling accurate patient workup prior 
to treatment for lymphoma11,12. This research involved a range of professional fi elds 
and provides evidence of multiprofessional working. 
Case study
An eight-year-old male presented with a painful right tibia; the clinical question 
surrounded whether this patient had an osteoid osteoma or leukaemia. A whole 
body bone scan was conducted (anterior and posterior) and a focal area of uptake 
was noted within the right femur. Subsequently, localised SPECT images of pelvis 
and femora were acquired; the poor resolution could not differentiate the high 
uptake between cortex and medulla and CT imaging was undertaken (see fi gure 
2). Correlation with plain fi lms and a SPECT-CT acquisition of the area show a 
localised area of thickening and sclerosis of the medial cortex of the upper right 
CT can be used 
with SPECT to 
localise cold or 
hot areas
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femoral shaft, and a small central lucent nidus with a surrounding sclerotic rim. 
The features are consistent with an osteoid osteoma.
Surgical resection of certain pathologies often requires quite precise localisation 
of lesions prior to surgery. This helps the surgeon locate the area to be removed 
more quickly; it also helps the surgeon plan more accurately which areas need 
to be removed. Better intelligence prior to and during surgery results in increased 
probability of removing the affected tissue and reduced operating time. Both can 
have an impact on post-operative recovery and, ultimately, patient outcome. 
Low dose/resolution and high dose/resolution can both play a part in localising 
lesions seen on SPECT studies, and the precise overlay of regional anatomy, 
together with co-registered SPECT-CT (structural and functional aspects) of the 
lesion make for better surgical localisation, possible radiotherapy treatment 
or, even, extraction of tumour tissue. For example, SPECT-CT of brain tumours 
using a range of Tc99m based radiopharmaceutical agents, such as Sestamibi 
and Tetrofosmin and In-111 Pentetreotide, may be utilised to provide accurate 
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radiotherapy/chemotherapy treatment. CT used in isolation cannot always 
distinguish tumour progression from radiotherapy damage/necrosis, even up to 
several months after the patient has received treatment14. 
Various empirical studies and critical reviews have demonstrated the additional 
value of SPECT-CT over stand alone SPECT systems, particularly in cases such as 
lymphoma21,22, infection and bone disease17. However, there appears to be a 
debate relating to the appropriate use of low dose CT for attenuation correction 
and/or basic localisation purposes (which were the parameters of a low 
performance x-ray scanning device) and higher quality CT data for improved 
anatomical image quality. Roach et al’s study in 200623 was conducted using 
a multislice SPECT-CT unit which permitted greater spatial resolution for the 
anatomical data. Although the overall fi nal diagnosis and reporter confi dence was 
improved using a multislice SPECT-CT unit, the increase over fi rst generation low-
performance SPECT-CT units was minimal.
Diagnosis using diagnostic quality CT
SPECT-CT has a role in diagnosis, particularly when ‘targeted’ SPECT imaging reveals 
lesions with no surrounding discernable anatomical landmarks (for localisation) 
and also when the internal structure of the SPECT lesion needs additional 
radiological (high resolution CT) scrutiny to determine its nature. An example could 
be differentiated thyroid cancer, using whole body imaging with iodine 123 or 
131. Here, the precise localisation of lesions is often not possible because of the 
absence of anatomical landmarks in nuclear medicine data. Co-registered SPECT-CT 
allows for differentiation between artefactual and normal uptake, and pathological 
uptake.
Research conducted by Roach et al highlighted the value of SPECT-CT in terms 
of diagnostic accuracy and reporter confi dence within clinical practice23. This 
evaluation of the impact of SPECT/CT on common areas of clinical practice, such 
as bone scintigraphy, infection imaging (Gallium-67), Indium-111 octreotide scans, 
I-123/1-131 MIBG scans/treatment monitoring, and Tc-99m Sestamibi parathyroid 
scans, refl ected a typical nuclear medicine department workload. Overall, the 
utilisation of SPECT-CT added extra confi dence to the fi nal diagnosis, and reporter 
confi dence was also increased in particular cases where anatomical landmarking 
would have been an issue without the CT data. The following case study 
demonstrates the clinical value of diagnostic accuracy using SPECT-CT. 
Case Study
A 78 year old female had known multiple liver metastases from a carcinoid 
tumour and Yttrium-90 therapy was being considered. An In-111 octreotide SPECT-
CT scan was conducted (see fi gure 3). As can be seen, the images demonstrate 
liver metastases, incidental adrenal gland fi ndings and hydronephrosis. The 
morphological appearance of the metastases can be clearly located on the 
diagnostic quality CT image series, giving heightened confi dence for areas of 
radiopharmaceutical uptake.
One of the biggest considerations of using low resolution or high dose CT scans 
in addition to SPECT is the additional radiation dose to the patient and whether or 
not the extra dose from using high-resolution CT is justifi ed, bearing in mind the 
extra clinical information that may be obtained. Table 1 illustrates radiation doses 
that a patient will typically receive from SPECT, low-resolution and high-resolution 
CT, and plain radiography for reference. As can be seen, the CT component adds 
a signifi cant amount to the total dose the patient receives; this is particularly true 
for high resolution CT. It is interesting to compare plain fi lm and high resolution CT 
and the dose differential. This brings into sharp focus the need to consider carefully 
whether CT or plain fi lm imaging would give the same radiological information 
and, if so, whether the lower dose alternative (plain fi lm) would be better justifi ed.
Professional responsibilities and legislative 
considerations
Depending upon local circumstances in clinical imaging departments, radiographers 
can be referrers, practitioners and operators within the context of the Ionising Radiation 
(Medical Exposure) Regulations2 (IR(ME)R). Within nuclear medicine and with regard 
to radiopharmaceuticals, this is not the case. Radiopharmaceuticals are regulated 
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Imaging and Dose (mSv)
SPECT [i] Low-Res CT[ii] High-Res CT[iii] Plain Film[iv]
Pulmonary Nodes Tc-99m Depreotide 6 Chest 1 Chest 5.8 Chest 0.02
Lumber Spine 
Metastases





Myocardial Imaging Tc-99m sestamibi 4 Chest 1 Chest 5.8 Chest 0.02
under both medicines and ionising radiation legislation and the former mandates that 
only a registered dental or medical practitioner may direct the clinical service and, as 
such, provide the clinical justifi cation required under IR(ME)R. For nuclear medicine 
examinations, with regard to IR(ME)R, only the ARSAC licence holder may justify 
clinical examinations. Radiographers working within nuclear medicine and with specifi c 
reference to radiopharmaceuticals may only act as operators.
Within nuclear medicine departments, legislative arrangements permit radiographers 
to act as practitioners and referrers for x-ray examinations and acting as referrer 
for plain x-ray examinations, in association with nuclear medicine procedures, has 
become common practice. Using the same legislative arrangements, radiographers 
can, indeed should, act as referrer and practitioner for the CT component of SPECT-CT. 
There is logic for both as SPECT-CT has limited routine applications. For many patients, 
the decision to make a CT exposure (low or high resolution) will depend on factors 
such as the clinical background, physical make up and the nuclear medicine images 
themselves. Hence, the decision to refer for CT may only be made at the point of 
care within the nuclear medicine department. Therefore, the radiographer is ideally 
placed to fulfi l the role of referrer. In full knowledge of the evidence base and the 
clinical background, a radiographer can act as practitioner, thereby protecting the 
patient from unnecessary x-radiation exposure. On discussion with several nuclear 
medicine departments, it was found that radiographers have already adopted 
formally the roles of referrer, practitioner and operator for the CT component of the 
SPECT-CT studies.
Business, practical and educational considerations 
when purchasing a SPECT-CT system
A department should consider the physical footprint required for a hybrid 
SPECT-CT system. This is especially true if the existing gamma camera has a 
small footprint. Some clinical departments within the United Kingdom are 
replacing fi rst generation SPECT systems with SPECT-CT units, which generally 
require a larger physical space. The space required for a SPECT-CT system will 
depend on the type of unit being installed and the nature of the examinations 
conducted. The quoted minimum room size for a GE Hawkeye/Hawkeye-
4 is 14 feet x 16 feet and the amount of lead shielding required for this 
environment may be less than a dedicated CT unit. Some departments utilise 
mobile lead shielding devices for the GE Hawkeye devices which permits some 
fl exibility with the organisation of the imaging environment. The exposure rate 
from low performance CT units is approximately 20 times less than that from a 
multislice CT unit24 and the use of mobile shields are common in departments 
with these units.
A larger physical room environment (minimum 15 feet x 24 feet) is required for 
SPECT-CT systems employing a dedicated multislice CT unit, and thicker protective 
shielding is required for the use of multislice SPECT/CT units. The weight bearing 
parameters of the fl oor should also be considered24, especially if the unit is not 
being installed on the ground level within a hospital. Separate operator console 
environments are also becoming common within SPECT-CT rooms, although this 
does remove an element of patient interaction normally associated with nuclear 
medicine.
Currently the cost of the high end CT components (eg 64 slice) may exceed the 
cost of the SPECT device and the justifi cation for such units will depend upon 
the clinical workload of a nuclear medicine department. With current shifts in 
imaging tools for certain conditions (eg pulmonary embolism), a SPECT-CT unit with 
multislice capabilities may be positioned to undertake contrast enhanced CT scans, 
such as pulmonary angiography and the assessment of coronary calcifi cation10,25 
and, potentially, providing a ’one stop‘ approach for patients undergoing their 
diagnostic CT and physiological scans, if required. 
 Table 1.
[i] Notes for Guidance on the Clinical Administration of Radiopharmaceuticals and Use of Sealed Radioactive Sources Health Protection Agency, 
Administration of Radioactive Substances Advisory Committee, March 2006 (Revised 20 April 2006).
[ii] Effective doses to patients from CT acquisitions on the GE Infi nia Hawkeye: a comparison of calculation methods.  Sawyer, L et al. Nuclear 
Medicine Communications. 29(2):144-149, February 2008.
[iii] Doses from computed tomography (CT) examinations in the UK – 2003 review Shrimpton PC et al. NRPB-W67 March 2005.
[iv] RADIATION PROTECTION 118 Referral guidelines for imaging, European Commission 1999.
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Nuclear medicine departments may wish to evaluate the feasibility of undertaking 
CT examinations during periods where access to radiopharmaceuticals is limited 
(eg early morning/late afternoon), or utilising the CT component of the hybrid 
unit for out-of-hours work to alleviate some of the demands on the radiology 
department’s main CT unit. This may require some degree of cross pollination of 
training requirements26 and the development of appropriate educational curriculum 
within the workplace and at academic institutions. Educational programmes for 
nuclear medicine technologists in North America and Australia provide focused 
academic and clinical training specifi cally related to the utilisation of CT within the 
nuclear medicine environment. 
In the USA, working relationships between the Society of Nuclear Medicine 
Technologists and the American Society for Radiologic Technologists are considered 
to be a good example of a synergistic approach to the training requirements 
between professions. The University of Sydney in Australia also offers a dedicated 
distance based CT module aimed at nuclear medicine technologists who are 
involved in using CT within a nuclear medicine environment. In the UK, there 
is limited scope for the provision of a dedicated hybrid imaging programme. 
However, short courses for technologists related to the safe use of CT, and hybrid 
imaging modules of study have emerged from two academic institutes over the 
last couple of years. Currently, it is unclear what CT training requirements are 
needed offi cially by a technologist working within the hybrid nuclear medicine 
fi eld, especially if the CT unit has a multislice confi guration and the imaging 
parameters are interchangeable. A clear educational strategy is required for 
the safe and optimal use of CT within a hybrid nuclear medicine environment, 
to minimise patient dose and optimise disease detection, aiding patient 
management. 
Conclusion
Following the inception of SPECT-CT hybrid technology, there appears to be an 
evolution in the useful applications associated with this modality. Initial ‘low-
end’ systems introduced over a decade ago provided a platform for improved 
anatomical localisation and high photon-fl ux attenuation co-effi cient data, 
potentially improving the sensitivity and specifi city of existing imaging techniques. 
Beyond the existing techniques, SPECT-CT has the potential for mirroring the 
success of PET-CT in terms of radiotherapy planning, dosimetry calculations and 
multi-imaging approaches, which include coronary artery calcium scoring and 
myocardial perfusion imaging.
As detector technology also continues to evolve, the overall design and utilisation 
of future SPECT/CT units may further develop. The use of solid state materials such 
as cadmium-zinc-telluride will provide a single detector interface and, potentially, 
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education of the hybrid imaging workforce is crucial to the future utilisation of this 
important area of clinical practice.
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